User menu

Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study

Bibliographic reference Powell, Jerry S. ; Apte, Shashikant ; Chambost, Hervé ; Hermans, Cédric ; Jackson, Shannon ; et. al. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. In: British Journal of Haematology, Vol. 168, no. 1, p. 124-134 (2015)
Permanent URL
  1. COLLINS P. W., MØSS J., KNOBE K., GROTH A., COLBERG T., WATSON E., Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX : Pharmacokinetic modeling: nonacog beta pegol (N9-GP), 10.1111/jth.12000
  2. Diao Lei, Li Shuanglian, Ludden Thomas, Gobburu Jogarao, Nestorov Ivan, Jiang Haiyan, Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B, 10.1007/s40262-013-0129-7
  3. HERMANS C., ALTISENT C., BATOROVA A., CHAMBOST H., DE MOERLOOSE P., KARAFOULIDOU A., KLAMROTH R., RICHARDS M., WHITE B., DOLAN G., , Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations, 10.1111/j.1365-2516.2008.01950.x
  4. Klitgaard Thomas, Nielsen Tina G., Overview of the human pharmacokinetics of recombinant activated factor VII, 10.1111/j.1365-2125.2007.03030.x
  5. Longo G., Messori A., Morfini M., Baudo F., Ciavarella N., Cinotti S., Filimberti E., Giustarini G., Molinari A. C., Ferrini Pierluigi Rossi, Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations, 10.1002/ajh.2830300305
  6. National Hemophilia Foundation 2007 MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding)
  7. Powell Jerry, Shapiro Amy, Ragni Margaret, Negrier Claude, Windyga Jerzy, Ozelo Margareth, Pasi John, Baker Ross, Potts James, Li Shuanglian, Mei Baisong, Pierce Glenn F., Robinson Brian, Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates, 10.1111/bjh.13109
  8. Powell Jerry S., Pasi K. John, Ragni Margaret V., Ozelo Margareth C., Valentino Leonard A., Mahlangu Johnny N., Josephson Neil C., Perry David, Manco-Johnson Marilyn J., Apte Shashikant, Baker Ross I., Chan Godfrey C., Novitzky Nicolas, Wong Raymond S., Krassova Snejana, Allen Geoffrey, Jiang Haiyan, Innes Alison, Li Shuanglian, Cristiano Lynda M., Goyal Jaya, Sommer Jurg M., Dumont Jennifer A., Nugent Karen, Vigliani Gloria, Brennan Aoife, Luk Alvin, Pierce Glenn F., Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B, 10.1056/nejmoa1305074
  9. Prasad Narayana, Padmanabhan Vinod, Mullaji Arun, Blood loss in total knee arthroplasty: an analysis of risk factors, 10.1007/s00264-006-0096-9
  10. QUON D. V. K., LOGAN L., Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine® SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis : HUMAN FACTOR IX AND SURGERY IN HAEMOPHILIA B, 10.1111/j.1365-2516.2010.02354.x
  11. RAGNI M. V., PASI K. J., WHITE G. C., GIANGRANDE P. L., COURTER S. G., TUBRIDY K. L., , Use of recombinant factor IX in subjects with haemophilia B undergoing surgery, 10.1046/j.1365-2516.2002.00587.x
  12. Rudowski Witold J., Scharf Romuald, Ziemski Jan M., Is major surgery in hemophiliac patients safe?, 10.1007/bf01658122
  13. Sommer J. M., Buyue Y., Bardan S., Peters R. T., Jiang H., Kamphaus G. D., Gray E., Pierce G. F., Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity : , 10.1160/th13-11-0971
  14. Srivastava A., Brewer A. K., Mauser-Bunschoten E. P., Key N. S., Kitchen S., Llinas A., Ludlam C. A., Mahlangu J. N., Mulder K., Poon M. C., Street A., , Guidelines for the management of hemophilia, 10.1111/j.1365-2516.2012.02909.x
  15. White, Thrombosis and Haemostasis, 78, 261 (1997)
  16. WINDYGA J., RUSEN L., GRUPPO R., O’BRIEN A. C., KELLY P., ROTH D. A, ARKIN S., BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study : BDDRFVIII FOR SURGICAL HAEMOSTASIS IN HAEMOPHILIA A, 10.1111/j.1365-2516.2010.02239.x
  17. Windyga J., Lissitchkov T., Stasyshyn O., Mamonov V., Rusen L., Lamas J. L., Oh M.-S., Chapman M., Fritsch S., Pavlova B. G., Wong W.-Y., Abbuehl B. E., Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B, 10.1111/hae.12228